findmyKOL
Clinical trialNCT00062244CompletedPhase 1/PHASE2Interventional

Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia

SponsorNational Cancer Institute (NCI)Enrollment58Waldenström Macroglobulinemia
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase I/II trial is studying the side effects and best dose of oblimersen and to see how well it works in treating patients with relapsed or refractory Waldenstrom's macroglobulinemia. Biological therapies such as oblimersen may interfere with the growth of the cancer cells and slow or stop the growth of Waldenstrom's macroglobulinemia.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Mayo Clinic in Arizona

    Scottsdale, Arizona, United States

  • Howard University Hospital

    Washington D.C., District of Columbia, United States

  • Mayo Clinic in Florida

    Jacksonville, Florida, United States

  • Johns Hopkins University

    Baltimore, Maryland, United States

  • University of Maryland Greenebaum Cancer Center

    Baltimore, Maryland, United States

  • Barbara Ann Karmanos Cancer Institute

    Detroit, Michigan, United States

  • Mayo Clinic

    Rochester, Minnesota, United States

  • University of Wisconsin Hospital and Clinics

    Madison, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Oblimersen sodium
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 May 2003
Primary completion
30 Jun 2007
Completion
—
Last update posted
4 Jun 2013
Registered enrollment
58
Registry id
NCT00062244
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.